OCULAR THERAPEUTIX, INC

OCULAR THERAPEUTIX, INC insiders are currently net sellers of OCUL stock, showing bearish sentiment over the past 90 days. Total sales of $74.9M outpace purchases of $39.0M, creating a net outflow of $35.9M.

OCULAR THERAPEUTIX, INC has 35 active insiders who have filed SEC Form 4 transactions in the past 90 days. Life Sciences Fund IV Strategic Partners, L. P. Sv (Executive) leads with 4 transactions totaling $24.6M. Road Llc Summer (Executive) follows with 34 transactions worth $23.4M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. OCULAR THERAPEUTIX, INC's current score of 34/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Feb 23, 2026, when Nayak Sanjay (Chief Strategy Officer) disposed of 1,759 shares at $8.28 per share for $14.6K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, OCUL insider trading sentiment is currently bearish with an Alignment Score of 34/100. The negative net flow of $35.9M shows more selling than buying. However, 4% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like OCULAR THERAPEUTIX, INC. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At OCUL, we track all Form 4 filings—currently showing 246 transactions from 35 insiders over 90 days.

A 10b5-1 plan allows OCULAR THERAPEUTIX, INC executives to pre-schedule stock sales when they don't possess material non-public information. At OCUL, approximately 4% of recent transactions are 10b5-1 trades. The remaining 96% are discretionary trades, which may carry more informational value.

You can monitor OCULAR THERAPEUTIX, INC (OCUL) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 35 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. OCULAR THERAPEUTIX, INC's current score of 34/100 indicates moderately bearish sentiment with selling outpacing buying. This is calculated from $39.0M in purchases versus $74.9M in sales over 90 days, resulting in a net flow of -$35.9M.

SEC Form 4 filings are mandatory reports that OCULAR THERAPEUTIX, INC insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At OCUL, the most common type is "S" with 21 occurrences. The most recent Form 4 was filed on Feb 23, 2026 by Nayak Sanjay.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At OCULAR THERAPEUTIX, INC, approximately 4% of recent transactions are executed under 10b5-1 plans, while 96% appear to be discretionary trades. The low percentage means most insider activity at OCUL represents discretionary decisions with more informational value.